Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT03665285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03665285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
NextCure, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 1, 2018
Completion date
April 11, 2023
Enrollment
109 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, breast cancer, cholangiocarcinoma, crc, endometrial cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, urothelial carcinoma